The Medicines Company Announces Clive Meanwell, MD, PhD, Chief Executive Officer, Is the Recipient of the 2016 Dr. Sol J. Barer Award for Vision, Innovation and Leadership

5 Feb 2016

Company also receives BioNJ Innovator Award for new drug approvals in 2015

PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 5, 2016-- The Medicines Company (NASDAQ:MDCO) today announced that its founder and Chief Executive Officer, Clive Meanwell, MD, PhD, has been awarded the 2016 Dr. Sol J. Barer Award for Vision, Innovation, and Leadership. Named for Sol J. Barer, PhD, founder and former Chairman and Chief Executive Officer of Celgene Corporation of Summit, New Jersey, the award recognizes outstanding research and business leaders who have made significant contributions to the growth and prosperity of the biosciences industry in New Jersey and throughout the world.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160205005411/en/

The award was presented last evening during ceremonies celebrating BioNJ’s 23rd Annual Dinner Meeting and Networking Event held at the Hilton East Brunswick. (click here to view Gala video).

“Dr. Sol Barer is an icon of the bioscience industry, and his dedication and commitment to innovation is nothing short of inspirational. I humbly accept this award on behalf of all of my colleagues at The Medicines Company who achieved so much during 2015 – and we thank the BioNJ Board of Trustees for this honor,” said Clive Meanwell, MD, PhD, Chief Executive Officer, The Medicines Company.

“Clive is everything a leader should be: a visionary who’s not afraid to challenge the status quo, an innovator who’s respected by patients and caregivers for his compassion and commitment to better understand their challenges, and a leader who knows how to get the job done and how to inspire a team to travel that road with him,” said Debbie Hart, President and Chief Executive Officer, BioNJ. “Since its inception in 1996, Clive has carefully guided The Medicines Company to the innovative institution it is today – known for developing products that industry experts have dubbed ‘game-changers’ in treating cardiovascular disease, infectious disease and sedation. At the same time, Clive has long been committed to understanding how customers value medicines, and ensuring the company delivers both medical and economic improvements that create value and build a sustainable business. Clive is so deserving of this award.”

At the same event, The Medicines Company was one of 16 companies who received a BioNJ Innovator Award for a new drug approval in 2015. The company had four drug approvals in the U.S. in 2015.

About the Dr. Sol J. Barer Award

The Dr. Sol J. Barer Award for Vision, Innovation, and Leadership was established by the BioNJ Board of Trustees in March 2008 as an annual award to recognize the outstanding research and business leaders who have made and continue to make significant contributions to the growth of the biosciences in New Jersey and around the world. The honoree is voted on by the BioNJ Board of Trustees from nominations taken from the Nominating Committee. The award is named for Dr. Sol J. Barer, Ph.D., who founded the biotechnology group at Celanese that was subsequently spun out to form Celgene, currently one of the world’s largest biotechnology companies.

About The Medicines Company

The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.

Source: The Medicines Company

The Medicines Company
Media:
Bob Laverty, +1-973-290-6162
Mobile: +1-609-558-5570
Vice President, Communications
Robert.Laverty@themedco.com
or
Investor Relations:
Krishna Gorti, MD, +1-973-290-6122
Vice President, Investor Relations
Krishna.Gorti@themedco.com